Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension.
The objective of this study was to determine whether a combination of inhaled nitric oxide (iNO) and O(2) is more effective than 100% O(2) or iNO alone for acute vasodilator testing in children. An open, prospective, randomized, controlled trial was conducted at 16 centers. Subjects were children 4 weeks to 18 years of age with pulmonary hypertension (PH) and increased pulmonary vascular resistance (PVR) undergoing right heart catheterization for acute vasodilator testing. All patients were tested with each of three agents (80 ppm iNO, 100% O(2), combination of 80 ppm iNO/100% O(2)) in three 10-min treatment periods, and hemodynamic measurements obtained. Primary outcome measures were percentages of acute responders with O(2) alone vs. iNO/O(2) and iNO alone vs. iNO/O(2). More patients on the combination were acute responders compared with O(2) or iNO alone (26% vs. 14%, P = 0.019, and 27% vs. 24%, P = 0.602, respectively). Changes in PVR index and mean pulmonary arterial pressure vs. baseline were greater with iNO/O(2) vs. either O(2) or iNO alone (P < 0.001). Survival at 1-year follow-up included (1) 90.9% of acute responders to the combination, compared with 77.8% of nonresponders to the combination, and (2) 85.7% of acute responders to O(2) alone, compared with 80.6% of nonresponders to O(2). Key conclusions are as follows. In children with PH and increased PVR, more acute responders were identified with the iNO/O(2) combination vs. O(2) alone. While there was no significant difference in acute responder rate with iNO alone vs. iNO/O(2), the combination improved pulmonary hemodynamics acutely better than iNO alone. One-year survival data show similar rates between the iNO/O(2) and the O(2) alone groups; however, the combination may be more effective than O(2) alone in discriminating survivors versus nonsurvivors at long-term follow-up.
Barst
Robyn J
RJ
Division of Pediatric Cardiology, Columbia University, Scarsdale, New York, NY 10583, USA. robyn.barst@barstconsulting.com
Agnoletti
Gabriella
G
Fraisse
Alain
A
Baldassarre
James
J
Wessel
David L
DL
D000280:Administration, Inhalation; D000293:Adolescent; D000704:Analysis of Variance; D006328:Cardiac Catheterization; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D010100:Oxygen / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D015996:Survival Rate; D014655:Vascular Resistance; D014664:Vasodilation / Q000187:drug effects*
D009569:Nitric Oxide; D010100:Oxygen
Circulation. 2004 Aug 10;110(6):660-5
15289375
Chest. 2001 Jan;119(1):128-36
11157594
Circulation. 2005 Jun 14;111(23):3105-11
15939821
Br Heart J. 1993 Nov;70(5):461-8
8260279
Br J Anaesth. 2007 May;98(5):657-61
17401143
Eur J Cardiothorac Surg. 1996;10(12):1120-6
10369648
J Heart Lung Transplant. 1994 May-Jun;13(3):366-75
8061011
Chest. 1986 Apr;89(4):497-503
2869919
Chest. 2004 Jul;126(1 Suppl):7S-10S
15249491
Respir Med. 2004 Mar;98(3):225-34
15002758
Lancet. 1991 Nov 9;338(8776):1173-4
1682593
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-S66
19555859
Circulation. 1999 Mar 9;99(9):1197-208
10069788
Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384-9
7842196
Circulation. 1961 Feb;23:241-52
13767207
J Am Coll Cardiol. 1999 Mar;33(3):813-9
10080486
Eur Respir J. 1998 Aug;12(2):265-70
9727772
Circulation. 1993 Feb;87(2):447-53
8425292
Circulation. 2009 Apr 28;119(16):2250-94
19332472
Circulation. 2002 Sep 24;106(12 Suppl 1):I76-81
12354713
N Engl J Med. 1992 Jul 9;327(2):76-81
1603139
Paediatr Anaesth. 2005 Dec;15(12):1083-8
16324028
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S78-S84
19555861
J Am Coll Cardiol. 2000 Dec;36(7):2204-11
11127462